Unraveling the Role of Ras Homolog Enriched in Brain (Rheb1 and Rheb2): Bridging Neuronal Dynamics and Cancer Pathogenesis Through Mechanistic Target of Rapamycin Signaling

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Feb 10

PMID 38338768

Authors

Mostafizur Rahman

Tuan Minh Nguyen

Gi Jeong Lee

Boram Kim

Mi Kyung Park

Chang Hoon Lee

Affiliations

Soon will be listed here.

Abstract

Ras homolog enriched in brain (Rheb1 and Rheb2), small GTPases, play a crucial role in regulating neuronal activity and have gained attention for their implications in cancer development, particularly in breast cancer. This study delves into the intricate connection between the multifaceted functions of Rheb1 in neurons and cancer, with a specific focus on the mTOR pathway. It aims to elucidate Rheb1's involvement in pivotal cellular processes such as proliferation, apoptosis resistance, migration, invasion, metastasis, and inflammatory responses while acknowledging that Rheb2 has not been extensively studied. Despite the recognized associations, a comprehensive understanding of the intricate interplay between Rheb1 and Rheb2 and their roles in both nerve and cancer remains elusive. This review consolidates current knowledge regarding the impact of Rheb1 on cancer hallmarks and explores the potential of Rheb1 as a therapeutic target in cancer treatment. It emphasizes the necessity for a deeper comprehension of the molecular mechanisms underlying Rheb1-mediated oncogenic processes, underscoring the existing gaps in our understanding. Additionally, the review highlights the exploration of Rheb1 inhibitors as a promising avenue for cancer therapy. By shedding light on the complicated roles between Rheb1/Rheb2 and cancer, this study provides valuable insights to the scientific community. These insights are instrumental in guiding the identification of novel targets and advancing the development of effective therapeutic strategies for treating cancer.

References

Odeniyide P, Yohe M, Pollard K, Vaseva A, Calizo A, Zhang L . Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma. Oncogene. 2022; 41(21):2973-2983. PMC: 9122815. DOI: 10.1038/s41388-022-02305-x. View

Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11(11):761-74. PMC: 3632399. DOI: 10.1038/nrc3106. View

Li Y, Wang Y, Kim E, Beemiller P, Wang C, Swanson J . Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb. J Biol Chem. 2007; 282(49):35803-13. DOI: 10.1074/jbc.M705231200. View

Gangoiti P, Arana L, Ouro A, Granado M, Trueba M, Gomez-Munoz A . Activation of mTOR and RhoA is a major mechanism by which Ceramide 1-phosphate stimulates macrophage proliferation. Cell Signal. 2010; 23(1):27-34. DOI: 10.1016/j.cellsig.2010.08.001. View

Neuman N, Henske E . Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis. EMBO Mol Med. 2011; 3(4):189-200. PMC: 3377068. DOI: 10.1002/emmm.201100131. View

Mazhab-Jafari M, Marshall C, Ho J, Ishiyama N, Stambolic V, Ikura M . Structure-guided mutation of the conserved G3-box glycine in Rheb generates a constitutively activated regulator of mammalian target of rapamycin (mTOR). J Biol Chem. 2014; 289(18):12195-201. PMC: 4007420. DOI: 10.1074/jbc.C113.543736. View

Armijo M, Campos T, Fuentes-Villalobos F, Palma M, Pincheira R, Castro A . Rheb signaling and tumorigenesis: mTORC1 and new horizons. Int J Cancer. 2015; 138(8):1815-23. DOI: 10.1002/ijc.29707. View

Mukhopadhyay S, Vander Heiden M, McCormick F . The Metabolic Landscape of RAS-Driven Cancers from biology to therapy. Nat Cancer. 2021; 2(3):271-283. PMC: 8045781. DOI: 10.1038/s43018-021-00184-x. View

Grondin R, Gash D . Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. J Neurol. 1998; 245(11 Suppl 3):P35-42. DOI: 10.1007/pl00007744. View

10.

Bai S, Hu S, Dai Y, Jin R, Zhang C, Yao F . promotes the proliferation of melanocytes to increase melanin deposition in Rex rabbits. Genome. 2022; 66(1):1-10. DOI: 10.1139/gen-2021-0111. View

11.

Arese M, Bussolino F, Pergolizzi M, Bizzozero L, Pascal D . Tumor progression: the neuronal input. Ann Transl Med. 2018; 6(5):89. PMC: 5890045. DOI: 10.21037/atm.2018.01.01. View

12.

Choi Y, Di Nardo A, Kramvis I, Meikle L, Kwiatkowski D, Sahin M . Tuberous sclerosis complex proteins control axon formation. Genes Dev. 2008; 22(18):2485-95. PMC: 2546692. DOI: 10.1101/gad.1685008. View

13.

Reiling J, Sabatini D . Stress and mTORture signaling. Oncogene. 2006; 25(48):6373-83. DOI: 10.1038/sj.onc.1209889. View

14.

Zou J, Zhou L, Du X, Ji Y, Xu J, Tian J . Rheb1 is required for mTORC1 and myelination in postnatal brain development. Dev Cell. 2011; 20(1):97-108. PMC: 3056331. DOI: 10.1016/j.devcel.2010.11.020. View

15.

Donovan S, Shannon K, Bollag G . GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta. 2002; 1602(1):23-45. DOI: 10.1016/s0304-419x(01)00041-5. View

16.

Vadysirisack D, Baenke F, Ory B, Lei K, Ellisen L . Feedback control of p53 translation by REDD1 and mTORC1 limits the p53-dependent DNA damage response. Mol Cell Biol. 2011; 31(21):4356-65. PMC: 3209328. DOI: 10.1128/MCB.05541-11. View

17.

Jeon M, Nam J, Shin W, Leem E, Jeong K, Jung U . In vivo AAV1 transduction with hRheb(S16H) protects hippocampal neurons by BDNF production. Mol Ther. 2014; 23(3):445-55. PMC: 4351465. DOI: 10.1038/mt.2014.241. View

18.

Manning B, Cantley L . Rheb fills a GAP between TSC and TOR. Trends Biochem Sci. 2003; 28(11):573-6. DOI: 10.1016/j.tibs.2003.09.003. View

19.

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

20.

Guo P, Qiao F, Huang D, Wu Q, Chen T, Badawy S . MiR-155-5p plays as a "janus" in the expression of inflammatory cytokines induced by T-2 toxin. Food Chem Toxicol. 2020; 140:111258. DOI: 10.1016/j.fct.2020.111258. View